Market Closed -
Nasdaq
04:00:00 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
1.39
USD
|
+2.96%
|
|
-6.71%
|
+18.80%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
119.3
|
132.5
|
164.1
|
67.41
|
73.02
|
100.9
|
-
|
-
|
Enterprise Value (EV)
1 |
101.9
|
116.2
|
133.6
|
19.16
|
73.02
|
79.63
|
113.2
|
129.4
|
P/E ratio
|
-3.58
x
|
-7.03
x
|
275
x
|
-2.04
x
|
-2.21
x
|
-2.39
x
|
-2.34
x
|
-2.34
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
54.9
x
|
16.8
x
|
5.55
x
|
50.8
x
|
8.88
x
|
179
x
|
13.7
x
|
3.84
x
|
EV / Revenue
|
46.9
x
|
14.7
x
|
4.52
x
|
14.4
x
|
8.88
x
|
142
x
|
15.4
x
|
4.93
x
|
EV / EBITDA
|
-3,385,883
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-3,760,800
x
|
-
|
-12,451,964
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
41,150
|
48,354
|
59,667
|
60,191
|
62,409
|
74,731
|
-
|
-
|
Reference price
2 |
2.900
|
2.740
|
2.750
|
1.120
|
1.170
|
1.350
|
1.350
|
1.350
|
Announcement Date
|
3/11/20
|
3/10/21
|
3/10/22
|
3/9/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.173
|
7.894
|
29.58
|
1.327
|
8.226
|
0.5625
|
7.358
|
26.26
|
EBITDA
|
-30.09
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-30.3
|
-17.94
|
-0.627
|
-30.28
|
-24.84
|
-36.34
|
-36.38
|
-31.14
|
Operating Margin
|
-1,394.57%
|
-227.2%
|
-2.12%
|
-2,281.61%
|
-302.02%
|
-6,459.64%
|
-494.44%
|
-118.55%
|
Earnings before Tax (EBT)
1 |
-30.77
|
-18.21
|
0.376
|
-32.95
|
-32.48
|
-42.76
|
-43.93
|
-45.78
|
Net income
1 |
-30.77
|
-18.21
|
0.376
|
-32.95
|
-32.48
|
-41.78
|
-42.03
|
-42.58
|
Net margin
|
-1,416.01%
|
-230.68%
|
1.27%
|
-2,482.82%
|
-394.91%
|
-7,428.21%
|
-571.22%
|
-162.12%
|
EPS
2 |
-0.8100
|
-0.3900
|
0.0100
|
-0.5500
|
-0.5300
|
-0.5650
|
-0.5775
|
-0.5767
|
Free Cash Flow
|
-27.09
|
-
|
-10.73
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-1,246.8%
|
-
|
-36.29%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/10/21
|
3/10/22
|
3/9/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
25.69
|
0.347
|
0.384
|
0.266
|
0.33
|
0.004
|
1.018
|
0.859
|
6.345
|
0.23
|
0.1225
|
0.1225
|
0.1225
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
18.71
|
-7.646
|
-7.837
|
-6.724
|
-8.07
|
-7.605
|
-7.27
|
-7.054
|
-2.915
|
-8.209
|
-9.218
|
-9.312
|
-9.601
|
-
|
-
|
Operating Margin
|
72.83%
|
-2,203.46%
|
-2,040.89%
|
-2,527.82%
|
-2,445.45%
|
-190,125%
|
-714.15%
|
-821.19%
|
-45.94%
|
-3,569.13%
|
-7,524.49%
|
-7,602.04%
|
-7,837.55%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
18.71
|
-7.644
|
-7.813
|
-7.827
|
-9.663
|
-9.28
|
-9.106
|
-9.267
|
-4.832
|
-11.76
|
-10.2
|
-10.26
|
-10.45
|
-
|
-
|
Net income
1 |
18.71
|
-7.644
|
-7.813
|
-7.827
|
-9.663
|
-9.28
|
-9.106
|
-9.267
|
-4.832
|
-11.76
|
-9.734
|
-9.825
|
-9.99
|
-
|
-
|
Net margin
|
72.83%
|
-2,202.88%
|
-2,034.64%
|
-2,942.48%
|
-2,928.18%
|
-232,000%
|
-894.5%
|
-1,078.81%
|
-76.15%
|
-5,114.35%
|
-7,946.29%
|
-8,020.41%
|
-8,154.94%
|
-
|
-
|
EPS
2 |
0.3100
|
-0.1300
|
-0.1300
|
-0.1300
|
-0.1600
|
-0.1500
|
-0.1500
|
-0.1500
|
-0.0800
|
-0.1700
|
-0.1340
|
-0.1280
|
-0.1320
|
-0.1100
|
-0.1300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/11/22
|
8/9/22
|
11/9/22
|
3/9/23
|
5/12/23
|
8/14/23
|
11/13/23
|
3/12/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
12.3
|
28.6
|
Net Cash position
1 |
17.4
|
16.3
|
30.4
|
48.3
|
-
|
21.3
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-27.1
|
-
|
-10.7
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.03
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
1.15%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/10/21
|
3/10/22
|
3/9/23
|
3/12/24
|
-
|
-
|
-
|
Last Close Price
1.35
USD Average target price
5.4
USD Spread / Average Target +300.00% Consensus |
1st Jan change
|
Capi.
|
---|
| +15.38% | 101M | | +12.30% | 118B | | +12.15% | 106B | | -8.14% | 23.4B | | -1.57% | 22.1B | | -8.33% | 18.34B | | -41.70% | 16.59B | | -15.33% | 15.97B | | +5.80% | 14.03B | | +28.03% | 11.67B |
Bio Therapeutic Drugs
|